IRX-2

Phase 2Biologic

BBrooklyn ImmunoTherapeutics, LLC

IRX-2 is one of 81 biologic programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Vulvar Intraepithelial NeoplasiaActive, not recruiting

Oral Cavity CancerActive, not recruiting

Squamous Cell CarcinomaActive, not recruiting

Breast CancerPhase 2

Active, not recruiting

Vulvar Intraepithelial NeoplasiaPhase 2

Active, not recruiting

Oral Cavity CancerPhase 1

Active, not recruiting

Squamous Cell CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Halaven

Eisai

Preclinical

38 2

Tykerb

GSK

Preclinical

80 3

Avastin

BBio-Thera Solutions

Preclinical

153 4

IRX-2

BBrooklyn ImmunoTherapeutics, LLC

Phase 2

1 5

Megace

Bristol-Myers Squibb

Preclinical

4 6

Voltaren

Novartis

Preclinical

1 7

Blenoxane

Bristol-Myers Squibb

Preclinical

1 8

Acupan

YYonsei University

Preclinical

1 9

Paracetamol

GSK

Preclinical

1 10

Zoladex

Luye Pharma Group Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Squamous Cell Carcinoma1 trial

IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity

Completed·BBrooklyn ImmunoTherapeutics, LLC·Phase 2·NCT02609386·105 enrolled

Breast Cancer1 trial

Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer

Active, not recruiting·PProvidence Health & Services·Phase 2·NCT04373031·12 enrolled

Vulvar Intraepithelial Neoplasia1 trial

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

Terminated·UUniversity of Southern California·Phase 2·NCT03267680·10 enrolled

Oral Cavity Cancer1 trial

Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer

Withdrawn·EEmory University·Phase 1·NCT03575234

Metastatic Solid Tumors1 trial

IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT03758781·12 enrolled

1 more indication

Head and Neck Cancer1 trial

A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer

Completed·BBrooklyn ImmunoTherapeutics, LLC·Phase 2·NCT00210470·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for IRX-2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IRX-2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IRX-2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Brooklyn ImmunoTherapeutics, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: BBrooklyn ImmunoTherapeutics, LLC

IRX-2

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Squamous Cell Carcinoma1 trial

Breast Cancer1 trial

Vulvar Intraepithelial Neoplasia1 trial

Oral Cavity Cancer1 trial

Metastatic Solid Tumors1 trial

Head and Neck Cancer1 trial

References

Drug Info

Quick Facts

Related News